Search

everythinglearnresearchcommunity

for

Search:↓

Breast cancer hormone therapy can cause hair loss, which can be treated with daily applications of specific topical solutions like minoxidil and hydrocortisone butyrate.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

The document concludes that non-operative treatment for gender dysphoria is safe and effective, and hormone therapy does not increase cancer risk.

The document says that hirsutism in women usually needs hair removal and hormone treatment to manage symptoms and improve well-being.

Endocrine therapies for cancer significantly increase the risk of hair loss.

Postmenopausal hyperandrogenism, a condition with symptoms like increased hair growth and acne, is usually caused by PCOS but can also be due to other factors. It's diagnosed by checking testosterone levels and treated either by removing the adrenal tumor or through antiandrogen therapy.

The document concludes that various drugs for men's health issues are in development, with treatments for sexual dysfunction and prostate conditions being the most advanced.

Male rats grow hair faster than females, and certain hormones can slow or slightly increase hair growth, but not significantly beyond natural rates.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.

Hormonal imbalances can cause hair loss, and understanding them can help develop better treatments.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.

Androgen deprivation therapy for prostate cancer can cause sexual, physical, and psychological side effects, and doctors should manage these carefully.

Gynecologists should provide comprehensive care for transgender patients, including mental health evaluation, hormone therapy, and surgical options, while monitoring for side effects and ensuring patient safety.

Hirsutism in women is often due to hormone sensitivity and has significant psychological effects.

Scalp cooling is the only FDA-approved method to prevent hair loss from chemotherapy, but other treatments like minoxidil and PRP are being tested.

The document concludes that personalized hormonal treatments are important for transgender individuals and more research is needed for non-binary treatments.

Mutations in certain receptors can cause diseases and offer new treatment options.

The document concludes that sex hormones are crucial for mammalian reproduction, health, and behavior, and require more research for therapeutic use.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Male hormones like testosterone may make COVID-19 worse, and testing for sensitivity to these hormones could help predict how severe a patient's symptoms might be. Treatments that reduce these hormones are being explored.

Long-term estrogen therapy in postmenopausal women can improve certain health markers, hair loss is common regardless of hormone use, stopping estrogen doesn't increase breast cancer risk, smoking does, and a balanced BMI is linked to lower mortality.

The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.

Current treatments for hair loss from chemotherapy are limited, but new methods are being researched.